Clinical trial · Observational
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are: 1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment; 2. How to obtain further information on the tumour biology of CTC; 3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Leukapheresis | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| leukapheresis | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of circulating tumor cells
- timeFrame
- The leukapheresis takes about 2 hours, and CTCs number will be measured in 24 hours after sampling.
- description
- Measurement of the number of CTCs enriched from different samples
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. male, aged 18-75 years; and 2. Evidence of metastasis (positive finding of metastasis on one of the following tests: CT and MRI; whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI; prostate-specific membrane antigen-targeted PET-CT); or clinical diagnosis of metastatic prostate cancer (tumour stage of T3 and above) by pathology of aspiration/surgical biopsy; 3. Good general condition, ECOG score 0-1, able to tolerate leukapheresis; 4. Normal haematological analysis, liver and renal function tests at screening; 5. Subjects (or their legal representatives) can understand the informed consent form. Exclusion Criteria: 1. those who have received systemic combination therapy for tumours within 5 years; 2. those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections 3. those with coagulation disorders, DIC or reduced platelets; 4. those receiving exogenous plasma at the time of the trial;
References
Publications (0)
Data not yet available